Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors
July 06 2022 - 6:00AM
Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system (CNS) disorders, today announced the
appointment of Michael Kamarck, Ph.D., to its board of directors
and his appointment to the Nominating and Corporate Governance
Committee. Dr. Kamarck is a seasoned biopharmaceutical executive
with over forty years of experience in discovery research, process
development and technical operations.
“We are thrilled to welcome Michael to our board as we continue
to advance our clinical programs in our mission to bring
transformative therapies to patients with CNS disorders,” said
Maxine Gowen, Ph.D., interim executive chairwoman of Passage Bio.
“His wealth of experience in manufacturing and technical
operations, critical areas for a genetic medicines company, will
provide valuable guidance as we continue to build on the strong
technical foundation we have established.”
Dr. Kamarck is the Chairman of the Sanofi Biotech Advisory
Council, providing strategic guidance to advance Sanofi’s
biologicals business. He recently retired as Chief Technology
Officer for Vir Biotechnology, Inc., where he led a multi-modality
technical approach to the development of treatments of serious
infectious diseases such as COVID-19 (sotrovimab), influenza and
hepatitis B. Prior to joining Vir, Dr. Kamarck was the Senior Vice
President of Global Vaccines and Biologics Manufacturing and
President of Merck BioVentures. In this role, he was responsible
for the worldwide manufacturing network in support of the vaccine
portfolio and biologics businesses. Dr. Kamarck also held numerous
senior executive positions at Wyeth Pharmaceuticals, including
President, Technical Operations and Product Supply as a member of
the Wyeth Management Team. While with Wyeth, he was responsible for
establishing a global biotechnology network of more than 10,000
employees to develop and manufacture numerous blockbuster products,
including building the manufacturing infrastructure to deliver the
global supply of Prevnar 13® and Enbrel®. Dr. Kamarck also spent 16
years at Bayer AG serving in numerous roles, including Senior Vice
President of Operations for Bayer Biologicals. He has authored more
than 50 peer-reviewed publications and has 20 issued patents. He
currently serves on the board of directors of Vaxcyte, Inc.
Dr. Kamarck holds a Ph.D. in biochemistry from the Massachusetts
Institute of Technology and a bachelor’s degree in biology from
Oberlin College.
“I am thrilled to join Passage Bio’s board and Nominating and
Governance Committee as the company enters an exciting phase of
clinical development and continues to build on its impressive
technical operations capabilities,” Dr. Kamarck said. “I look
forward to partnering with the Board and management team to ensure
Passage Bio remains at the leading edge of manufacturing and
technical capabilities as we plan for continued clinical success,
moving closer to bringing these therapies to patients with
devastating CNS disorders.”
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines
company on a mission to provide life-transforming therapies for
patients with CNS diseases with limited or no approved treatment
options. Our portfolio spans pediatric and adult CNS indications,
and we are currently advancing three clinical programs in GM1
gangliosidosis, Krabbe disease and frontotemporal dementia with
several additional programs in preclinical development. Based in
Philadelphia, PA, our company has established a strategic
collaboration and licensing agreement with the renowned University
of Pennsylvania’s Gene Therapy Program to conduct our discovery and
IND-enabling preclinical work. Through this collaboration, we have
enhanced access to a broad portfolio of gene therapy candidates and
future gene therapy innovations that we then pair with our deep
clinical, regulatory, manufacturing and commercial expertise to
rapidly advance our robust pipeline of optimized gene therapies. As
we work with speed and tenacity, we are always mindful of patients
who may be able to benefit from our therapies. More information is
available at www.passagebio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of, and made pursuant to the safe harbor provisions of,
the Private Securities Litigation Reform Act of 1995, including,
but not limited to: our expectations about the ability of our lead
product candidates to treat their respective target monogenic CNS
disorders. These forward-looking statements may be accompanied by
such words as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,”
“potential,” “possible,” “will,” “would,” and other words and terms
of similar meaning. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements, including: our ability to
develop and obtain regulatory approval for our product candidates;
the timing and results of preclinical studies and clinical trials;
risks associated with clinical trials, including our ability to
adequately manage clinical activities, unexpected concerns that may
arise from additional data or analysis obtained during clinical
trials, regulatory authorities may require additional information
or further studies, or may fail to approve or may delay approval of
our drug candidates; the occurrence of adverse safety events; the
risk that positive results in a preclinical study or clinical trial
may not be replicated in subsequent trials or success in early
stage clinical trials may not be predictive of results in later
stage clinical trials; failure to protect and enforce our
intellectual property, and other proprietary rights; our dependence
on collaborators and other third parties for the development and
manufacture of product candidates and other aspects of our
business, which are outside of our full control; risks associated
with current and potential delays, work stoppages, or supply chain
disruptions caused by the coronavirus pandemic; and the other risks
and uncertainties that are described in the Risk Factors section in
documents the company files from time to time with the Securities
and Exchange Commission (SEC), and other reports as filed with the
SEC. Passage Bio undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
For further information, please contact:
Passage Bio Investors:Stuart HendersonPassage
Bio267-866-0114shenderson@passagebio.com
Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare
Communications312-961-2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Apr 2024 to May 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From May 2023 to May 2024